Pharmalot… Pharmalittle… The Weekend Nears

By Ed Silverman And so, another working week is drawing to a close. And not a moment too soon. Unfortunately, we continue to experience technical difficulties – our hard drive crashed ...

FTC Asks Supreme Court To Review Pay To Delay

By Ed Silverman The US Supreme Court is being asked to review yet another so-called ‘pay-to-delay’ case. The latest request has been made by the US Solicitor General – at the ...

Pharma, Pollution & Patchwork Laws: Vic Explains

By Ed Silverman Three months ago, Alameda County in California pass an ordinance that requires drugmakers to pay for the disposal of unused and expired prescription medicines. The move, ...

FDA & Compounders: More Oversight Needed?

By Ed Silverman Over the past two years, compounded medications have figured in two highly controversial episodes. In one instance, Roche attempted to prevent ophthalmologists from ...

Takeda continues buying spree, picks up LigoCyte

By Eric Palmer Having made a series of large acquisitions that significantly broadened its reach, Japan’s Takeda Pharmaceutical today announced a $60 million plus deal that ...

J&J settles Risperdal cases, avoiding former FDA commish’s testimony

By Eric Palmer Johnson & Johnson has again backed down on its defense of Risperdal cases alleging that it caused boys who were given the antipsychotic to grow breasts. Johnson ...

Mayne Pharma to pay $120 millon for Metrics

CDMO Metrics makes niche products for itself and others By Eric Palmer Mayne Pharma, an Australia-based drugmaker, has jumped the Pacific to buy Metrics, a privately owned U.S. niche ...

NICE reverses position on new use for Novartis’ Lucentis

Discount does the trick in new move in eye drug competition By Eric Palmer The U.K.’s drug price watchdog apparently achieved the effect it intended when it earlier turned its ...

Race for copy of Rituxan gets yet another entrant

Boehringer Ingelheim will try simultaneous trial for U.S. and EU By Eric Palmer The race to ready copies of Roche’s ($RHHBY) super-selling rheumatoid arthritis drug Rituxan in ...

The Medicines Co. abandons blood-loss drug over safety risk

By Ryan McBride The Medicines Company has ditched development of an experimental drug to lessen loss of blood in surgeries after spotting patient safety problems in a Phase IIb study, ...

UPDATED: Bay Area biotech KaloBios reveals IPO ambitions

By Ryan McBride KaloBios Pharmaceuticals wants to go public. The South San Francisco developer of monoclonal antibody drugs has announced plans for an initial public offering. It’s ...

GSK hands back antibiotic candidate to Anacor Pharmaceuticals

By Ryan McBride GlaxoSmithKline ($GSK) has officially ended its development of an experimental antibiotic after halting enrollment in trials for the candidate early this year, handing ...
Page 1 of 10512345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS